The SingHealth Duke-NUS Academic Medical Centre draws on the collective strengths of SingHealth and Duke-NUS Medical School to drive the transformation of healthcare and provide affordable, accessible, quality healthcare. With over 40 clinical specialties, a network of acute hospitals, national specialty centres, polyclinics and community hospitals, it delivers comprehensive, multi-disciplinary and integrated care. To enhance community care, the new Outram Community Hospital on SGH Campus will be completed in 2020.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Industrial Impact

BEIGENE ANNOUNCES APPROVAL FOR BRUKINSA (ZANUBRUTINIB) BY SWISSMEDIC FOR TREATMENT OF ADULT PATIENTS WITH WALDENSTRÖMS MACROGLOBULINEMIA

BeiGene | February 18, 2022

news image

BeiGene a global, science-driven biotechnology company focused on developing innovative and affordable medicines, today announced that BeiGene’s BTK inhibitor BRUKINSA received approval from Swissmedic for the treatment of adult patients with Waldenström’s macroglobulinemia who have received at least one prior line of therapy, or for treatment-naïve patients who are not suited for standard chemo-immunotherapy. BRUKINSA had previously been granted orphan drug status. ...

Read More

Medical

SOPHIA GENETICS LAUNCHES NEW SOLUTION TO ADVANCE CHRONIC LYMPHOCYTIC LEUKEMIA CARE, IN COLLABORATION WITH IDIBAPS

biotech, biotechnology, cell, gene, tissue | June 10, 2022

news image

SOPHiA GENETICS (Nasdaq: SOPH), the Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) of Barcelona, and the Spanish Diagnóstica Longwood today announced from the European Hematology Association Congress in Vienna that they have combined their expertise to develop a new Chronic Lymphocytic Leukemia (CLL) solution to advance CLL care. This collaboration will unify the wide variety of current guideline recommendations into one single application aiming to improve ...

Read More

Medical

MATICA BIO LAUNCHES MATIMAX™ CELL LINES AT BIO INTERNATIONAL CONVENTION

Businesswire | June 07, 2023

news image

Matica Biotechnology, Inc. a contract development and manufacturing organization specializing in the GMP production of cell and gene therapies, today unveiled the company’s new MatiMax™ cell lines at the BIO International Convention, taking place in Boston, MA.. Proprietary to Matica Bio, MatiMaxTM HEK293 and HEK293T cell lines have been rigorously optimized to enable. Faster doubling times – Reaching as low as 17 hours, which can significan...

Read More

Research

QUANTGENE DEMONSTRATES GAME-CHANGING SEQUENCING PRECISION IN GENES, A LEADING SCIENTIFIC JOURNAL

Quantgene | June 08, 2021

news image

Quantgene, biotechnology, cloud, and AI company located in Santa Monica, CA, and Berlin, Germany, has demonstrated the most exact gene sequencing yet published in the industry, as shown in the February edition of GENES, a major scientific journal in medical genomics. "Precision Genomics is revolutionizing medicine, but it is being hampered by a lack of rapid, accurate, and easily accessible technology," said Jo Bhakdi, CEO of Quantgene. "Today, the protection of hum...

Read More
news image

Industrial Impact

BEIGENE ANNOUNCES APPROVAL FOR BRUKINSA (ZANUBRUTINIB) BY SWISSMEDIC FOR TREATMENT OF ADULT PATIENTS WITH WALDENSTRÖMS MACROGLOBULINEMIA

BeiGene | February 18, 2022

BeiGene a global, science-driven biotechnology company focused on developing innovative and affordable medicines, today announced that BeiGene’s BTK inhibitor BRUKINSA received approval from Swissmedic for the treatment of adult patients with Waldenström’s macroglobulinemia who have received at least one prior line of therapy, or for treatment-naïve patients who are not suited for standard chemo-immunotherapy. BRUKINSA had previously been granted orphan drug status. ...

Read More
news image

Medical

SOPHIA GENETICS LAUNCHES NEW SOLUTION TO ADVANCE CHRONIC LYMPHOCYTIC LEUKEMIA CARE, IN COLLABORATION WITH IDIBAPS

biotech, biotechnology, cell, gene, tissue | June 10, 2022

SOPHiA GENETICS (Nasdaq: SOPH), the Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) of Barcelona, and the Spanish Diagnóstica Longwood today announced from the European Hematology Association Congress in Vienna that they have combined their expertise to develop a new Chronic Lymphocytic Leukemia (CLL) solution to advance CLL care. This collaboration will unify the wide variety of current guideline recommendations into one single application aiming to improve ...

Read More
news image

Medical

MATICA BIO LAUNCHES MATIMAX™ CELL LINES AT BIO INTERNATIONAL CONVENTION

Businesswire | June 07, 2023

Matica Biotechnology, Inc. a contract development and manufacturing organization specializing in the GMP production of cell and gene therapies, today unveiled the company’s new MatiMax™ cell lines at the BIO International Convention, taking place in Boston, MA.. Proprietary to Matica Bio, MatiMaxTM HEK293 and HEK293T cell lines have been rigorously optimized to enable. Faster doubling times – Reaching as low as 17 hours, which can significan...

Read More
news image

Research

QUANTGENE DEMONSTRATES GAME-CHANGING SEQUENCING PRECISION IN GENES, A LEADING SCIENTIFIC JOURNAL

Quantgene | June 08, 2021

Quantgene, biotechnology, cloud, and AI company located in Santa Monica, CA, and Berlin, Germany, has demonstrated the most exact gene sequencing yet published in the industry, as shown in the February edition of GENES, a major scientific journal in medical genomics. "Precision Genomics is revolutionizing medicine, but it is being hampered by a lack of rapid, accurate, and easily accessible technology," said Jo Bhakdi, CEO of Quantgene. "Today, the protection of hum...

Read More

Resources

resource image

Cell and Gene Therapy, Industrial Impact

Best Practices for RIM Business Process Automation

Whitepaper

resource image

Cell and Gene Therapy, MedTech

Multi-Specific Monoclonal Antibodies

Whitepaper

resource image

Cell and Gene Therapy, Industrial Impact

Best Practices for RIM Business Process Automation

Whitepaper

resource image

Cell and Gene Therapy, MedTech

Multi-Specific Monoclonal Antibodies

Whitepaper

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us